161 related articles for article (PubMed ID: 32423482)
1. DPD status and fluoropyrimidines-based treatment: high activity matters too.
Chamorey E; Francois E; Etienne MC; Ferrero JM; Peyrade F; Barranger E; Bozec A; Largillier R; Cassuto O; Viotti J; Schiappa R; Milano G
BMC Cancer; 2020 May; 20(1):436. PubMed ID: 32423482
[TBL] [Abstract][Full Text] [Related]
2. Toxicities associated with chemotherapy regimens containing a fluoropyrimidine: A real-life evaluation in France.
Barin-Le Guellec C; Lafay-Chebassier C; Ingrand I; Tournamille JF; Boudet A; Lanoue MC; Defossez G; Ingrand P; Perault-Pochat MC; Etienne-Grimaldi MC
Eur J Cancer; 2020 Jan; 124():37-46. PubMed ID: 31715555
[TBL] [Abstract][Full Text] [Related]
3. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
4. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy.
Mercier C; Ciccolini J
Clin Colorectal Cancer; 2006 Nov; 6(4):288-96. PubMed ID: 17241513
[TBL] [Abstract][Full Text] [Related]
5. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
[TBL] [Abstract][Full Text] [Related]
6. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
7. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Smorenburg CH; Peters GJ; van Groeningen CJ; Noordhuis P; Smid K; van Riel AM; Dercksen W; Pinedo HM; Giaccone G
Ann Oncol; 2006 Jan; 17(1):35-42. PubMed ID: 16251201
[TBL] [Abstract][Full Text] [Related]
9. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Elander NO; Aughton K; Ghaneh P; Neoptolemos JP; Palmer DH; Cox TF; Campbell F; Costello E; Halloran CM; Mackey JR; Scarfe AG; Valle JW; McDonald AC; Carter R; Tebbutt NC; Goldstein D; Shannon J; Dervenis C; Glimelius B; Deakin M; Charnley RM; Anthoney A; Lerch MM; Mayerle J; Oláh A; Büchler MW; Greenhalf W;
Br J Cancer; 2018 Apr; 118(7):947-954. PubMed ID: 29515256
[TBL] [Abstract][Full Text] [Related]
10. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
11. Tumor dihydropyrimidine dehydrogenase in stage II and III colorectal cancer: low level expression is a beneficial marker in oral-adjuvant chemotherapy, but is also a predictor for poor prognosis in patients treated with curative surgery alone.
Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Atsushi Nanashima ; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
Cancer Lett; 2004 Feb; 204(1):97-104. PubMed ID: 14744539
[TBL] [Abstract][Full Text] [Related]
12. Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
Sukkarieh HH; AlSagoor T; Alnuhait M; Bustami R; Bryson S; Adem FMK; Abdalla H; Karbani G
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1704. PubMed ID: 36806724
[TBL] [Abstract][Full Text] [Related]
13. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer.
Tsuji T; Sawai T; Takeshita H; Nakagoe T; Hidaka S; Yamaguchi H; Yasutake T; Nagayasu T; Tagawa Y
Cancer Chemother Pharmacol; 2004 Dec; 54(6):531-6. PubMed ID: 15309506
[TBL] [Abstract][Full Text] [Related]
14. Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy.
Hakamada Y; Tsuchida A; Arima M; Kubouchi T; Tokita H; Ota D; Kaise H; Aoki T; Kusama M; Aoki T
Int J Mol Med; 2005 Aug; 16(2):309-14. PubMed ID: 16012767
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
16. [Relationship between dihydropyrimidine dehydrogenase(DPD) activity and toxicity of 5-FU-based adjuvant chemotherapy in colorectal cancer patients].
Zhou ZW; Wang GQ; Wan DS; Pan ZZ; Li S; Chen G; Liao H
Ai Zheng; 2004 Nov; 23(11 Suppl):1512-6. PubMed ID: 15566669
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of the efficacy and safety of capecitabine or tegafur, gimeracil and oteracil potassium capsules combined with oxaliplatin chemotherapy regimens in the treatment of advanced gastric cancer].
Wan Y; Hui H; Wang X; Wu J; Sun S
Zhonghua Zhong Liu Za Zhi; 2016 Jan; 38(1):28-34. PubMed ID: 26796803
[TBL] [Abstract][Full Text] [Related]
19. Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy.
van Kuilenburg AB; Klumpen HJ; Westermann AM; Zoetekouw L; Bakker PJ; Guchelaar HJ; Richel DJ
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):726-32. PubMed ID: 18600532
[TBL] [Abstract][Full Text] [Related]
20. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]